These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34220666)

  • 21. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
    Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
    J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
    Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
    Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease course in mdx:utrophin+/- mice: comparison of three mouse models of Duchenne muscular dystrophy.
    McDonald AA; Hebert SL; Kunz MD; Ralles SJ; McLoon LK
    Physiol Rep; 2015 Apr; 3(4):. PubMed ID: 25921779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-dependent diffusion MRI as a probe of microstructural changes in a mouse model of Duchenne muscular dystrophy.
    Porcari P; Hall MG; Clark CA; Greally E; Straub V; Blamire AM
    NMR Biomed; 2020 May; 33(5):e4276. PubMed ID: 32101354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
    Miglietta D; De Palma C; Sciorati C; Vergani B; Pisa V; Villa A; Ongini E; Clementi E
    Orphanet J Rare Dis; 2015 Aug; 10():101. PubMed ID: 26296873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair.
    McIntosh L; Granberg KE; Brière KM; Anderson JE
    NMR Biomed; 1998 Feb; 11(1):1-10. PubMed ID: 9608583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan.
    Preethy S; Aoki Y; Minegishi K; Iwasaki M; Senthilkumar R; Abraham SJK
    Sci Rep; 2023 Oct; 13(1):17008. PubMed ID: 37813938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electromyographic studies in mdx and wild-type C57 mice.
    Han JJ; Carter GT; Ra JJ; Abresch RT; Chamberlain JS; Robinson LR
    Muscle Nerve; 2006 Feb; 33(2):208-14. PubMed ID: 16281275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.
    Ponnusamy S; Sullivan RD; You D; Zafar N; He Yang C; Thiyagarajan T; Johnson DL; Barrett ML; Koehler NJ; Star M; Stephenson EJ; Bridges D; Cormier SA; Pfeffer LM; Narayanan R
    Hum Mol Genet; 2017 Jul; 26(13):2526-2540. PubMed ID: 28453658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.
    Burns DP; Rowland J; Canavan L; Murphy KH; Brannock M; O'Malley D; O'Halloran KD; Edge D
    Exp Physiol; 2017 Sep; 102(9):1177-1193. PubMed ID: 28665499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FVB Background Does Not Dramatically Alter the Dystrophic Phenotype of Mdx Mice.
    Wasala NB; Zhang K; Wasala LP; Hakim CH; Duan D
    PLoS Curr; 2015 Feb; 7():. PubMed ID: 25737807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological features of masticatory muscles after botulinum toxin A injection into the right masseter muscle of dystrophin deficient (mdx-) mice.
    Botzenhart UU; Gredes T; Gerlach R; Zeidler-Rentzsch I; Gedrange T; Keil C
    Ann Anat; 2020 May; 229():151464. PubMed ID: 31978572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.
    González-Sánchez J; Sánchez-Temprano A; Cid-Díaz T; Pabst-Fernández R; Mosteiro CS; Gallego R; Nogueiras R; Casabiell X; Butler-Browne GS; Mouly V; Relova JL; Pazos Y; Camiña JP
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1063-1078. PubMed ID: 30216693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.
    Levi O; Genin O; Angelini C; Halevy O; Pines M
    Oncotarget; 2015 Sep; 6(27):23249-60. PubMed ID: 26015394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse.
    Farini A; Meregalli M; Belicchi M; Battistelli M; Parolini D; D'Antona G; Gavina M; Ottoboni L; Constantin G; Bottinelli R; Torrente Y
    J Pathol; 2007 Oct; 213(2):229-38. PubMed ID: 17668421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy.
    Desguerre I; Arnold L; Vignaud A; Cuvellier S; Yacoub-Youssef H; Gherardi RK; Chelly J; Chretien F; Mounier R; Ferry A; Chazaud B
    Muscle Nerve; 2012 Jun; 45(6):803-14. PubMed ID: 22581532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.